Assessing the Clinical Importance of Statistically Significant Improvement in Anti-Dementia Drug Trials

Publisher： Karger

E-ISSN： 1423-0208|20|2|51-56

ISSN： 0251-5350

Source： Neuroepidemiology, Vol.20, Iss.2, 2001-05, pp. : 51-56

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Gottfries-Bråne-Steen Scale: Validity, Reliability and Application in Anti-Dementia Drug Trials

By  

Dementia and Geriatric Cognitive Disorders, Vol. 12, Iss. 1, 2000-12 ,pp. : 1-14

Karger

Access to resources Recommend Favorite

Global Change Assessments in Anti-Alzheimer Clinical Drug Trials

By  

Dementia and Geriatric Cognitive Disorders, Vol. 9, Iss. 3, 1998-10 ,pp. : 8-15

Karger

Access to resources Recommend Favorite

Adequacy of Using Consensus Guidelines for Diagnosis of Dementia with Lewy Bodies in Clinical Trials for Drug Development

By  

Dementia and Geriatric Cognitive Disorders, Vol. 41, Iss. 1-2, 2015-12 ,pp. : 55-67

Karger

Access to resources Recommend Favorite

Evaluation of Factors of Importance for Clinical Dementia Diagnosis

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 5-6, 2005-04 ,pp. : 289-298

Karger

Access to resources Recommend Favorite

Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials

By  

Dementia and Geriatric Cognitive Disorders, Vol. 20, Iss. 6, 2005-11 ,pp. : 338-344

Karger

Access to resources Recommend Favorite